AstraZeneca Archives

SRC Family Kinase Inhibitor as a Potential Treatment for Fragile X Syndrome

May 7, 2023

This $100,000 FRAXA grant will fuel the Smith lab’s new approach to treating Fragile X syndrome using Saracatinib, originally a cancer drug.

FXS Patients’ Social Deficits are Linked to Social Anxiety, Eye-tracking Study Says

February 4, 2019

Dr. Craig Erickson and colleagues at the University of Cincinnati used eye-tracking technology to understand sociability in Fragile X syndrome. This study affirms what so many parents, caretakers, and educators suspect: people with fragile X want to be social, and it is anxiety – not lack of interest – which usually hold them back. If anxiety could be reduced, more sociability would likely follow. Dr. Erickson is a Fragile X expert and FRAXA investigator who is currently conducting a Fragile X clinical trial of an investigational new drug.

FRAXA Funded Researchers Present at MA Fragile X Conference

April 9, 2018

Boston Children’s Hospital hosted a Fragile X conference with FRAXA-funded researchers Dr. Craig Erickson & Dr. Carol Wilkinson presenting.

Takeaways from Fragile X Advocacy Day

March 29, 2018

At my first Fragile X Advocacy Day, I met with Congress and families, advocating together for research and hope.

Craig Erickson, MD, Cincinnati Children's Hospital

Fragile X Clinical Trial of AZD7325 in Adults

February 1, 2018

FRAXA funded a trial of AZD7325, a drug that boosts GABA(A), in adults with Fragile X. Led by Dr. Craig Erickson, it also tested innovative biomarkers for future trials.

Brain Imbalance Target of Dr. Erickson’s New Clinical Trial

October 25, 2017

Dr. Erickson’s trial targeted brain imbalance in Fragile X by boosting GABA signaling with AZD7325, aiming to restore excitatory–inhibitory balance and improve symptoms.

Development of a Novel GABA-A Agonist in Fragile X Syndrome

September 9, 2013

FRAXA funded analysis of a selective GABA-A drug for Fragile X, leading to a clinical trial at Cincinnati Children’s to test this potential treatment.

SRC Family Kinase Inhibitor as a Potential Treatment for Fragile X Syndrome

FXS Patients’ Social Deficits are Linked to Social Anxiety, Eye-tracking Study Says

FRAXA Funded Researchers Present at MA Fragile X Conference

Takeaways from Fragile X Advocacy Day

Fragile X Clinical Trial of AZD7325 in Adults

Brain Imbalance Target of Dr. Erickson’s New Clinical Trial

Development of a Novel GABA-A Agonist in Fragile X Syndrome

Support FRAXA

Get In Touch!

Explore Fragile X & Research

Get FRAXA Updates